Metrion Biosciences

Metrion Biosciences is a rapidly growing, private UK-based CRO specializing in ion channel screening and preclinical services for cardiac safety and neuroscience. Founded in 2015, it has established itself as a leader in electrophysiology-based assays, including GLP hERG testing, hiPSC-cardiomyocyte assays, and native tissue neuroscience models. The company's value proposition lies in its deep scientific expertise, high-quality data output, and ability to support clients from early discovery through regulatory stages. Its recognition in The Sunday Times 100 Tech list underscores its status as a fast-growing technology company in the life sciences sector.

Specialist ion channel screening platform utilizing automated and manual electrophysiology, hiPSC-derived cardiomyocytes for cardiac safety, and native tissue/brain slice assays for neuroscience. Services include high-throughput screening, cell line generation, GLP hERG testing, and CiPA-compliant assays.

Competes with large, full-service preclinical CROs (e.g., Charles River, Labcorp) that offer ion channel services, as well as other specialist electrophysiology CROs. Differentiation is based on deep ion channel expertise, high-quality data, niche neuroscience/cardiac safety assays, and a collaborative, scientifically engaged service model rather than just transactional screening.